In silico mutation analysis of human beta globin gene in sickle cell disease patients

Authors

  • Hira Mubeen University of South Asia, Lahore
  • Rubab Zahra Naqvi National Institute for Biotechnology and Genetic Engineering, Faisalabad
  • Ammara Masood National Institute for Biotechnology and Genetic Engineering, Faisalabad
  • Muhammad Waseem Shoaib District Head Quarter (DHQ), Faisalabad
  • Shahid Raza University of South Asia, Lahore

DOI:

https://doi.org/10.18203/2320-6012.ijrms20161247

Keywords:

Substitution, Sickle shaped, Hemoglobin, Evolutionary pathway

Abstract

Background: Sickle cell disease is an inherited blood disorder that affects red blood cells. People with sickle cell conditions make a different form of hemoglobin a called hemoglobin S. Sickle cell conditions are inherited from parents in much the same way as blood type, hair color and texture, eye color and other physical traits. Sickle cell disease occurs due to a single mutation on the b-globin gene, namely, a substitution of glutamic acid for valine at position 6 of the b chain. Several mutations in HBB gene can cause sickle cell disease. Abnormal versions of beta-globin can distort red blood cells into a sickle shape. The sickle-shaped red blood cells die prematurely, which can lead to anemia. The study is focused on analysis of HBB gene with its different variants, Evolutionary pathways and protein domains by using various bioinformatics tools.

Methods: The study is focused on analysis of HBB gene with its different variants, Evolutionary pathways and protein domains by using various bioinformatics tools.

Results: Sickle cell disease occurs due to a single mutation on the b-globin gene, namely, a substitution of glutamic acid for valine at position 6 of the b chain. Several mutations in HBB gene can cause sickle cell disease. Abnormal versions of beta-globin can distort red blood cells into a sickle shape. Comparative study shown 38 different genes with little genetic variation among different species.

Conclusion: Studies suggested that there is need to maintain a primary prevention program to detect sickle cell disease at earlier stages despite having a large high risk. Preventive diagnosis and follow-up would reduce infant mortality by preventing the development of severe anemia as well as dangerous complications. In short, sickle cell disease surveillance would avert loss of life, measured as the number of years lost due to ill-health, disability or early death.

 

References

Silva WS, Lastra A, Oliveira SF, Guimarães NK, Grisolia CK. Avaliaçao da cobertura do programa de triagem neonatal de hemoglobinopatias em populações do Recôncavo Baiano, Brasil Cad Saúde Pública. 2006;22(12):2561-6.

Diniz D, Guedes C, Barbosa L, Tauil PL, Magalhães I. Prevalência do traço e da anemia falciforme em recém-nascidos do Distrito Federal, Brasil, 2004 a 2006 Cad Saúde Pública. 2009;25(1):188-94.

Sommer CK, Goldbeck AS, Wagner SC, Castro SM. Triagem neonatal para hemoglobinopatias: experiência de um ano na rede de saúde pública do Rio Grande do Sul, Brasil Cad Saúde Pública. 2006;22(8):1709-14.

Lobo CL, Bueno LM, Moura P, Ogeda LL, Castilho S, Carvalho SM. Triagem neonatal para hemoglobinopatias no Rio de Janeiro. Brasil Pan Am J Public Health. 2003;13(2/3):154-9.

Gelpi AP. Migrant populations and the diffusion of the sickle cell gene. Ann Intern Med. 1973;79:258-64.

Kulozik AE, Wainscoat JS, Serjeant GR, Kar BC, Al-Awamy B, Essan GJ et al. Geographical survey of beta S-globin gene haplotypes: evidence for an independent asian origin of sickle-cell mutation. Am J Hum Genet. 1986;39:239-44.

Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343-60.

Chui DH, Dover GJ. Sickle cell disease: no longer a single gene disorder. Curr Opin Pediatr. 2001;13:22-7.

Lisowski L, Sadelain M. Current status of globin gene therapy for the treatment of β-thalassaemia. Br J Haematol. 2008;141(3):335-45.

Gelinas RE, Bender MA, Miller AD, Novak U. Long-term expression of the human β-globin gene after retroviral transfer into pluripotent hematopoietic stem cells of the mouse. Adv Exp Med Biol. 1989;271:135-48.

Gelinas RE, Bender MA, Miller AD, Novak U. Regulated expression of the human β-globin gene after retroviral transfer into murine and human hematopoietic cells. Prog Clin Biol Res. 1989;316B:235-49.

May C, Rivella S, Callegari J, Heller G, Karen ML Gaensler, Lucio Luzzatto. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature. 2000;406(6791):82-6.

Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368-71.

Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. Correction of murine sickle cell disease using γ-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther. 2008;17(2):245-52.

Nagela RL, Bookchina RM, Johnsona J, Labieb D, Wajcmanb H, William A. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA. 1979;76(2):670-2.

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467(7313):318-22.

World Health Organization. Sickle-cell anaemia. Report by the Secretariat. Fifty-ninth World Health Assembly. Provisional agenda item 11.4. A59/9. WHO. 2006. Last accessed on 2006.

Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine. Baltimore. 2005; 84:363-76.

Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med. 1994;148(8):796-804.

Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology and therapeutic approaches. Scientific World Journal. 2008;8:1295-324.

Lane PA, Witkowska HE, Falick AM, Houston ML, McKinna JD. Hemoglobin D Ibadan - beta-0-thalassemia: detection by neonatal screening and confirmation by electrospray-ionization mass spectrometry. Am J Hematol. 1993;44:158-61.

Strickland DK, Ware RE, Kinney TR. Pitfalls in newborn hemoglobinopathy screening: failure to detect beta-thalassemia. J Pediatr. 1995;127:304-8.

Witkowska HE, Lubin BH, Beuzard Y, Baruchel S, Esseltine DW, Vichinsky EP. Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. N Engl J Med. 1991;325:1150-4.

Downloads

Published

2016-12-30

How to Cite

Mubeen, H., Naqvi, R. Z., Masood, A., Shoaib, M. W., & Raza, S. (2016). In silico mutation analysis of human beta globin gene in sickle cell disease patients. International Journal of Research in Medical Sciences, 4(5), 1673–1677. https://doi.org/10.18203/2320-6012.ijrms20161247

Issue

Section

Original Research Articles